source
- Ionis shares tumble over $1 billion as Tryngolza sales forecast cut in halfIonis Pharmaceuticals saw its market value drop by more than $1 billion after it lowered its sales outlook for Tryngolza, a triglyceride‑lowering therapy. The company now expects $50 million in sa…
- Coherus shrinks headcount 30% to narrow focus of cancer comboCoherus Oncology is once again laying off 30% of its workforce as the biopharma narrows the focus of its CCR8-targeting antibody on esophageal cancer.Fierce Biotech · 6h ago↗ source
- FDA approves Bayer’s Sunharbo, first Factor XIa inhibitor to lower stroke recurrence risk